AU6262598A - Anti-viral guanosine-rich tetrad forming oligonucleotides - Google Patents

Anti-viral guanosine-rich tetrad forming oligonucleotides

Info

Publication number
AU6262598A
AU6262598A AU62625/98A AU6262598A AU6262598A AU 6262598 A AU6262598 A AU 6262598A AU 62625/98 A AU62625/98 A AU 62625/98A AU 6262598 A AU6262598 A AU 6262598A AU 6262598 A AU6262598 A AU 6262598A
Authority
AU
Australia
Prior art keywords
oligonucleotide
htv
virus
oligonucleotides
viral
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU62625/98A
Other languages
English (en)
Inventor
Paul A. Cossum
Michael E Hogan
Joshua O Ojwang
Robert F Rando
Thomas L Wallace
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Baylor College of Medicine
Aronex Pharmaceuticals Inc
Original Assignee
Aronex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/987,574 external-priority patent/US6150339A/en
Application filed by Aronex Pharmaceuticals Inc filed Critical Aronex Pharmaceuticals Inc
Publication of AU6262598A publication Critical patent/AU6262598A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • C12N15/1132—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses against retroviridae, e.g. HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/15—Nucleic acids forming more than 2 strands, e.g. TFOs
    • C12N2310/151—Nucleic acids forming more than 2 strands, e.g. TFOs more than 3 strands, e.g. tetrads, H-DNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/18—Type of nucleic acid acting by a non-sequence specific mechanism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/335—Modified T or U
AU62625/98A 1997-02-04 1998-02-03 Anti-viral guanosine-rich tetrad forming oligonucleotides Abandoned AU6262598A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US3737497P 1997-02-04 1997-02-04
US60037374 1997-02-04
US08/987,574 US6150339A (en) 1993-04-23 1997-12-09 Anti-viral guanosine-rich oligonucleotides
US07987574 1997-12-09
PCT/US1998/001974 WO1998033807A1 (en) 1997-02-04 1998-02-03 Anti-viral guanosine-rich tetrad forming oligonucleotides

Publications (1)

Publication Number Publication Date
AU6262598A true AU6262598A (en) 1998-08-25

Family

ID=26714074

Family Applications (1)

Application Number Title Priority Date Filing Date
AU62625/98A Abandoned AU6262598A (en) 1997-02-04 1998-02-03 Anti-viral guanosine-rich tetrad forming oligonucleotides

Country Status (4)

Country Link
EP (1) EP0971944A4 (de)
AU (1) AU6262598A (de)
CA (1) CA2279488A1 (de)
WO (1) WO1998033807A1 (de)

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3687808A (en) * 1969-08-14 1972-08-29 Univ Leland Stanford Junior Synthetic polynucleotides
US4388306A (en) * 1980-06-04 1983-06-14 Merck & Co., Inc. Pharmaceutical composition comprising modified polyriboinosinic-polyribocytidylic acid, for induction of interferon in primates
FR2567892B1 (fr) * 1984-07-19 1989-02-17 Centre Nat Rech Scient Nouveaux oligonucleotides, leur procede de preparation et leurs applications comme mediateurs dans le developpement des effets des interferons
GB8717430D0 (en) * 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
US5176996A (en) * 1988-12-20 1993-01-05 Baylor College Of Medicine Method for making synthetic oligonucleotides which bind specifically to target sites on duplex DNA molecules, by forming a colinear triplex, the synthetic oligonucleotides and methods of use
US5397702A (en) * 1989-03-06 1995-03-14 The Regents Of The University Of California Assay for and treatment of autoimmune diseases
US5075217A (en) * 1989-04-21 1991-12-24 Marshfield Clinic Length polymorphisms in (dC-dA)n ·(dG-dT)n sequences
US5173426A (en) * 1989-10-06 1992-12-22 Yale University DNAs encoding genetically engineered low oxygen affinity mutants of human hemoglobin
DE4216134A1 (de) * 1991-06-20 1992-12-24 Europ Lab Molekularbiolog Synthetische katalytische oligonukleotidstrukturen
US5523389A (en) * 1992-09-29 1996-06-04 Isis Pharmaceuticals, Inc. Inhibitors of human immunodeficiency virus
US5567604A (en) * 1993-04-23 1996-10-22 Aronex Pharmaceuticals, Inc. Anti-viral guanosine-rich oligonucleotides
US5591721A (en) * 1994-10-25 1997-01-07 Hybridon, Inc. Method of down-regulating gene expression
AU725936B2 (en) * 1995-07-19 2000-10-26 Aronex Pharmaceuticals, Inc. Anti-viral guanosine-rich oligonucleotides

Also Published As

Publication number Publication date
CA2279488A1 (en) 1998-08-06
EP0971944A4 (de) 2005-01-26
EP0971944A1 (de) 2000-01-19
WO1998033807A1 (en) 1998-08-06

Similar Documents

Publication Publication Date Title
US6150339A (en) Anti-viral guanosine-rich oligonucleotides
US6323185B1 (en) Anti-viral guanosine-rich oligonucleotides and method of treating HIV
EP1007657B1 (de) Hiv-spezifische oligonukleotide und verfahren zu deren verwendung
EP0664833B1 (de) Therapeutisches anti-hiv oligonukleotid und arzneimittel
US5523389A (en) Inhibitors of human immunodeficiency virus
Ojwang et al. T30177, an oligonucleotide stabilized by an intramolecular guanosine octet, is a potent inhibitor of laboratory strains and clinical isolates of human immunodeficiency virus type 1
JP2798305B2 (ja) アンチセンスオリゴヌクレオチドおよびヒト免疫不全ウイルス感染におけるその使用
US6288042B1 (en) Anti-viral guanosine-rich tetrad forming oligonucleotides
WO1994008004A9 (en) Therapeutic anti-hiv oligonucleotide and pharmaceutical
AU725936B2 (en) Anti-viral guanosine-rich oligonucleotides
AU6262598A (en) Anti-viral guanosine-rich tetrad forming oligonucleotides
WO1998033807A9 (en) Anti-viral guanosine-rich tetrad forming oligonucleotides
Boiziau et al. A phosphorothioate oligonucleotide blocks reverse transcription via an antisense mechanism
Fujihashi et al. Short, terminally phosphorylated oligoriboguanylic acids effectively inhibit cytopathicity caused by human immunodeficiency virus
Agrawal Antisense oligonucleotide-based therapy for HIV-1 infection from laboratory to clinical trials
WO2002068582A2 (en) Phosphorothioate (p=s) oligonucleotides containing modified nucleotides with six-membered azasugars and use for aids therapy thereof
WO1998003646A1 (en) Compositions and methods for treating specific gene expression-related diseases and disorders in humans
Galderisi et al. Antisense oligonucleotides as drugs for HIV treatment
WO1997048795A2 (en) Compositions and methods for treating specific gene expression-related diseases and disorders in humans
CA2396240A1 (en) Methods for inhibiting/treating hiv infections and aids related symptoms
EP1007656A1 (de) Veränderte proteinkinase a-spezifische oligonukleotide und verfahren ihrer anwendung

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted